Pyrimethamine-sulfadoxine resistance in Plasmodium falciparum must be delayed in Africa.
Rieckmann
Karl
K
Cheng
Qin
Q
D000349:Africa; D000655:Amodiaquine / Q000627:therapeutic use; D000818:Animals; D000962:Antimalarials / Q000494:pharmacology*; D037621:Artemisinins / Q000627:therapeutic use; D000077332:Artesunate; D004338:Drug Combinations; D004351:Drug Resistance / Q000235:genetics; D006801:Humans; D016778:Malaria, Falciparum / Q000188:drug therapy*; D010963:Plasmodium falciparum / Q000235:genetics / Q000254:growth & development* / Q000378:metabolism; D011739:Pyrimethamine / Q000494:pharmacology*; D012717:Sesquiterpenes / Q000627:therapeutic use; D013413:Sulfadoxine / Q000494:pharmacology*
D000962:Antimalarials; D037621:Artemisinins; D004338:Drug Combinations; D012717:Sesquiterpenes; D000655:Amodiaquine; C001205:fanasil, pyrimethamine drug combination; D000077332:Artesunate; D013413:Sulfadoxine; D011739:Pyrimethamine